Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine

Trial Profile

A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Frovatriptan (Primary) ; Zolmitriptan
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Menarini
  • Most Recent Events

    • 15 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
    • 15 Jun 2019 Status changed from recruiting to completed.
    • 12 Oct 2016 This trial is completed in Ireland (End date: 2008-11-03) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top